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88.1 %. The median operative time and surgical blood loss 
were 260 min (range, 210–334) and 500 ml (range, 393–
898), respectively. The 5-year PFS rate was 67.2 %, and the 
5-year OS rate was 68.0 %. In multivariate analysis, lymph 
node metastasis before NAC [hazard ratio (HR), 34.88] and 
non-response to NAC (HR 30.58) were significant prognos-
tic factors.
Conclusion NAC with the CDDP/CPT-11 regimen 
achieves a high antitumor efficacy with moderate adverse 
reactions, allowing safe radical hysterectomy, and is thus 
considered to be a useful therapeutic method that can 
improve prognosis.
Keywords Cervical cancer · Bulky mass · NAC · CDDP · 
CPT-11
Introduction
Therapeutic methods for stage IB2 to IIB cervical cancer 
with a bulky mass differ between Japan and Western coun-
tries. Based on the results of large-scale randomized studies 
and meta-analyses, concurrent chemoradiotherapy (CCRT) 
is recommended as the standard treatment in Western coun-
tries [1–5]. However, an approach using neoadjuvant chem-
otherapy (NAC) is widely applied clinically in Japan, South 
Korea, China, and Italy [6]. Irinotecan (CPT-11), a drug 
developed in Japan, is reportedly useful as monotherapy or 
in combination with cisplatin (CDDP) for recurrent cervi-
cal cancer [7, 8]. We previously reported the efficacy and 
safety of a treatment regimen involving a 28-day cycle of 
CDDP administered on day 1 and CPT-11 on days 1, 8, and 
15 [9].
From the aspect of reducing the time to surgical therapy 
as the primary treatment, we conducted a phase II clinical 
Abstract 
Background We examined the efficacy and safety of neo-
adjuvant chemotherapy (NAC) with the CPT-11 + CDDP 
regimen in combination with radical hysterectomy.
Subjects and methods The subjects were 42 patients with 
stages IB2 to IIIB squamous cell carcinoma of the uterine 
cervix with a bulky mass. CDDP at 70 mg/m2 was intrave-
nously administered on day 1 and CPT-11 at 70 mg/m2 was 
intravenously administered on days 1 and 8 of a 21-day 
cycle. In principle, two cycles were administered followed 
by radical hysterectomy. We examined antitumor efficacy, 
adverse events, completion rate of radical hysterectomy, 
operative time, surgical blood loss, progression-free sur-
vival (PFS), and overall survival (OS).
Results The antitumor effect was complete response in 7 
patients, partial response in 28, stable disease in 6, and pro-
gressive disease in 1; the response rate was 83.3 % (95 % 
confidence interval, 68.6–93.0). Grade 3 or more severe 
neutropenia, anemia, and platelet count decreases were 
noted in 23 (54.8 %), 4 (9.5 %), and 1 (2.4 %) patient, 
respectively. Grade 3 nausea occurred in 3 patients (7.1 %), 
vomiting in 1 (2.4 %), and grade 3 febrile neutropenia in 2 
(7.1 %). The completion rate of radical hysterectomy was 
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study of NAC in combination with radical hysterectomy 
with a dosing schedule employing a 21-day cycle with a 
higher than usual CDDP dose intensity.
Subjects and methods
Subjects
The subjects were 42 patients with stages IB2 to IIIB squa-
mous cell carcinoma of the uterine cervix with a bulky 
mass. These patients gave informed consent and were 
scheduled to undergo radical hysterectomy during the 
period from June 2002 to March 2014.
Justification for the target sample size
We previously reported that the response rate to the CPT-
11/CDDP regimen [CPT-11 60 mg/m2 (days 1, 8, 15), 
CDDP 70 mg/m2 (day 1) q28 days] was 59 % [9]. Accord-
ingly, the threshold response rate was set at 50 %, because 
it would not be worthwhile to use this strategy in a clini-
cal setting if the response rate was significantly lower 
than 50 %. The response rates to platinum-based NAC in 
patients with cervical cancer reportedly range from 76 % to 
95 % [6, 10, 11]. Accordingly, the expected response rate 
was set at 80 %, anticipating that the response rate to this 
regimen would be 80 %. The number of patients required 
was calculated to be 36 based on a presumed binominal dis-
tribution with a threshold value of 59 %, expected response 
rate of 80 %, and two-sided α-level of 0.05 and β-level of 
0.2 (1 − β = 0.8). The number of planned subjects was 
thus set at 40 patients, taking into account the possibility of 
a few patients becoming ineligible or dropping out.
Inclusion criteria
The following set of inclusion criteria was employed for 
selection of study subjects. (1) Histologically verified squa-
mous cell carcinoma of the uterine cervix; (2) age more 
than 20 years and less than 70 years; (3) locally advanced 
stage IB2 to IIIB; (4) Eastern Cooperative Oncology 
Group (ECOG) performance status (PS) 0–2; (5) initially 
treated case; (6) presence of a magnetic resonance imag-
ing (MRI)-measurable bulky mass in the uterine cervix; (7) 
hematological and blood biochemical findings meeting the 
following criteria (WBC count ≥4,000/mm3; neutrophil 
count ≥2,000/mm3; platelet count ≥100,000/mm3; hemo-
globin ≥10.0 g/dl; AST and ALT levels ≤2 times the upper 
limit of normal reference range at study site; serum total 
bilirubin level ≤1.5 mg/dl; serum creatinine ≤1.5 mg/dl; 
and creatinine clearance ≥60 ml/min); (8) life expectancy 
≥6 months; and (9) written informed consent personally 
given by the subject.
Exclusion criteria
Exclusion criteria were prescribed as follows. (1) Patients 
with overt infection; (2) patients with a serious complica-
tion (e.g., cardiac disease, poorly controlled diabetes mel-
litus, malignant hypertension, bleeding tendency); (3) 
patients with active multiple cancer; (4) patients with inter-
stitial pneumonia or pulmonary fibrosis; (5) patients with 
effusions; (6) patients with a history of unstable angina or 
myocardial infarction within 6 months after registration, or 
with a concurrent serious arrhythmia requiring treatment; 
(7) patients for whom treatment with cisplatin and irinote-
can is contraindicated; (8) patients with (watery) diarrhea; 
(9) patients with intestinal paralysis or ileus; (10) pregnant 
women, nursing mothers, or women wishing to become 
pregnant; (11) patients with a history of serious drug hyper-
sensitivity or drug allergy; and (12) patients who were 
inadequate for safe conduct of this study as judged by the 
attending physician.
Neoadjuvant chemotherapy
CDDP at 70 mg/m2 was intravenously administered on day 
1 and CPT-11 at 70 mg/m2 was intravenously administered 
on days 1 and 8 of a 21-day cycle. In principle, two cycles 
were administered followed by radical hysterectomy.
Dose modification criteria
1. Criteria for CPT-11 dose skip. The CPT-11 dose on day 
8 will be skipped if hematological test values within 
2 days before day 8 fail to fulfill the following crite-
ria: (1) neutrophil count ≥1,000/mm3, and (2) platelet 
count ≥75,000/mm3.
2. Criteria for initiation of the second cycle. Initiation of 
the second cycle will be postponed up to a maximum 
of 2 weeks if hematological test values within 2 days 
before the scheduled second cycle initiation day fail 
to fulfill the following criteria: (1) neutrophil count 
≥1,500/mm3, (2) platelet count ≥75,000/mm3, and (3) 
serum creatinine ≤1.5 mg/dl.
Dose reduction criteria
The doses of cisplatin and irinotecan will be reduced to 
70 and 60 mg/m2, respectively, in the second course for 
patients for whom any of the following signs of toxicity is 
noted in the first cycle: (1) grade 4 neutropenia persisting 
for ≥7 days, (2) febrile neutropenia persisting for ≥4 days, 
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(3) grade 4 thrombocytopenia, (4) grade 3 thrombocytope-
nia with hemorrhage, and (5) grade ≥3 nonhematological 
toxicity excluding nausea, vomiting, appetite loss, fatigue, 
and hair loss.
Supportive therapy
Therapeutic administration of granulocyte-colony-stimu-
lating factor (G-CSF) preparations was undertaken when 
grade 4 neutropenia was noted in the first cycle. In the sec-
ond cycle and thereafter, prophylactic use of the prepara-
tion in patients with grade 3 neutropenia was acceptable 
if grade 4 neutropenia had been noted in the first cycle. 
Antiemetics were used for preventive purposes.
Endpoints/variables
The primary endpoint was antitumor efficacy, and the sec-
ondary endpoints were adverse events, completion rate of 
radical hysterectomy, operative time, surgical blood loss, 
progression-free survival (PFS), and overall survival (OS). 
Antitumor efficacy, PFS, and OS were also calculated by 
stage.
For the determination of antitumor efficacy, MRI was 
performed after the completion of course 1 and course 2, 
using MRI images before treatment as the baseline. Anti-
tumor efficacy was determined using the Response Evalu-
ation Criteria in Solid Tumors (RECIST) version 1.1, with 
response being the best evaluation. Adverse events were 
evaluated according to the National Cancer Institute Com-
mon Toxicity Criteria (NCI-CTCAE) version 4.0.
Main treatment
Stage Ib2–IIIb patients were subjected to a radical hyster-
ectomy unless the antitumor response was progression of 
disease or up-stage progression. A radical hysterectomy 
was performed on stage IIIb patients with a down-stage 
progression. As a rule, lymph node dissection included the 
lymph nodes within the pelvis (external iliac nodes, inter-
nal iliac nodes, common iliac nodes, suprainguinal nodes, 
parametrial nodes, and obturator nodes). Concurrent chem-
oradiation therapy (CCRT) was carried out for patients 
whose conditions were inoperable.
Postoperative adjuvant therapy
Patients with a positive surgical margin, metastatic lymph 
nodes, infiltration to the parametrium, and/or vascular 
invasion, as demonstrated by pathological examination 
of the resected specimens, underwent postoperative irra-
diation, chemotherapy or CCRT. Before 2008, irradiation 
was performed as postoperative adjuvant therapy, whereas 
chemotherapy was performed from 2008 onward. However, 
CCRT was performed for patients who had multiple lymph 
node metastases and/or infiltration to the parametrium.
Statistical analysis
Progression-free survival and overall survival were cal-
culated from the date of start of NAC, to the documented 
date of progression, death, or last follow-up, whichever 
occurred first. Impact of surgery result on survival was 
assessed by constructing Kaplan–Meier curves with a log-
rank test. Cox regression analyses were performed to assess 
the prognostic factors on survival. All reported significance 
was two tailed at a level of 0.05.
Results
Clinical characteristics
Among 43 patients enrolled, 1 was diagnosed as having 
glassy cell carcinoma based on the postoperative histo-
pathological examination. Therefore, we analyzed the other 
42 patients. The median age was 45 years (range, 25–63). 
The performance status was 0 in 37 patients and 1 in 5, 
and clinical progression was stage IB2 in 9 patients, stage 
IIA2 in 2, stage IIB2 in 27, and stage IIIB in 4. Histologi-
cal subtypes were keratinizing type in 11 patients and non-
keratinizing type in 31. Computed tomography before NAC 
showed lymph node metastasis in 16 patients and no lymph 
node metastasis in 26. The tumor size was less than 5 cm 
in 18 patients and 5 cm or more in 24 by MRI before NAC. 
Thirteen patients were positive and 29 patients were nega-
tive for pathological lymph node metastasis. Postoperative 
treatments were radiation therapy in 13 patients, chemo-
therapy in 15, and chemoradiotherapy in 3; no postopera-
tive treatment was given to 9 patients (Table 1).
Response
The antitumor effect was complete response (CR) in 7 
patients, partial response (PR) in 28, stable disease (SD) 
in 6, and progressive disease (PD) in 1, and the response 
rate was 83.3 % [95 % confidence interval (CI), 68.6–93.0]. 
Response rates by progression were 100 % for stage I, 
82.8 % for stage II, and 50.0 % for stage III (Table 2).
Adverse events
Grades 3 and 4 neutropenia were observed in 11 (26.2 %) 
and 12 (28.6 %) patients, respectively. Grade 3 or more 
severe anemia was noted in 4 patients (9.5 %); among them, 
a patient with grade 4 anemia required a blood transfusion. 
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Grade 3 or more severe decreases in platelet counts were 
observed in 1 patient (2.4 %). As grade 3 or more severe 
nonhematological toxicity, grade 3 nausea occurred in 3 
patients (7.1 %), vomiting in 1 (2.4 %), and grade 3 febrile 
neutropenia in 2 (7.1 %) (Table 3).
Among the total 42 patients, 40 (95.2 %) completed 
chemotherapy as scheduled. The administration of CPT-11 
on day 8 of cycle 2 was skipped in the remaining 2 patients. 
Grade 3 nausea persisted in these 2 patients; although it did 
not satisfy the skip criteria, in both cases the primary physi-
cian decided to skip the administration. The administration 
in cycle 2 was postponed in 3 patients (10.7 %) because 
neutrophil counts did not satisfy the therapy initiation cri-
teria; however, all these 3 patients were able to receive 
treatment within 7 days. In 2 patients (10.0 %) in whom 
febrile neutropenia continued for 4 days or more, the doses 
of CPT-11 and CDDP were reduced from 70 to 60 mg/m2.
Operative details
Among the total 42 patients, 2 with stage IIIB had inopera-
ble disease. Forty patients underwent surgery. Radical hys-
terectomy was performed for 38 patients, but in 1 of them 
surgery was incomplete because of difficulty in resecting 
the lymph node metastasis. Simple total hysterectomy and 
exploratory laparotomy were performed in 1 patient each. 
The operable rate of surgery was 95.2 %; completion rate 
of radical hysterectomy was 88.1 % (Fig. 1). Median num-
ber of lymph nodes dissected was 22 (range, 3–49); median 
operative time was 260 min (range, 210–334); median 
blood loss was 500 ml (range, 393–898). Blood transfu-
sions were given to 6 of 40 patients (15.0 %). The median 
time from surgery to discharge was 21 days (range, 16–26) 
(Table 4).
PFS and OS analysis
Of the 38 patients who underwent radical hysterectomy 
(excluding 1 patient who underwent probelaparotomy), 
10 patients (26.3 %) developed tumor recurrence, that is, 
recurrence was noted in 1 (50.0 %) of the 2 patients who 
received postoperative CCRT, 2 (13.3 %) of the 15 patients 
who received postoperative chemotherapy, 5 (41.7 %) of 
the 12 patients who received postoperative radiotherapy, 
and 2 (22.2 %) of the 9 patients who did not receive post-
operative adjuvant therapy (Table 5). Tumor recurrence 
in the lymph nodes was noted in 4 patients (affecting the 
paraaortic lymph nodes in all 4 cases and accompanied 
by metastasis to the subclavicular lymph nodes in 1 case). 
Of the 4 patients unable to undergo radical hysterectomy, 
1 patient underwent CCRT after a simple total hyster-
ectomy. CCRT was used for the patient who underwent 
Table 1  Patient characteristics
Characteristic n = 42
Age (years)






 Keratinizing type/non-keratinizing type 11/31
Preoperative lymph node metastasis
 Positive/negative 16/26
Tumor diameter
 >5 cm/<5 cm 24/18







Table 2  Response (n = 42)
CR complete response, PR partial response, SD stable disease, PD 
progressive disease
CR PR SD PD Objective response (CR + PR)
Total (n = 42) 7 28 6 1 35 (83.3 %)
Stage l (n = 9) 2 7 0 0 9 (100 %)
Stage ll (n = 29) 2 20 4 1 24 (82.8 %)
Stage lll (n = 4) 1 1 2 0 2 (50.0 %)
Table 3  Adverse events (n = 42)
Grade 1 Grade 2 Grade 3 Grade 4 Grade >3
Hematological toxicity
 Leukopenia 8 20 8 3 11 (26.2)
 Neutropenia 4 14 11 12 23 (54.8)
 Anemia 17 20 3 1 4 (9.5)
 Thrombocyto-
penia
10 2 1 0 1 (2.4)
Nonhematological toxicity
 Nausea 25 9 3 0 3 (7.1)
 Vomiting 21 7 1 0 1 (2.4)
 Diarrhea 4 2 0 0 0 (0)
 Creatinine 2 0 0 0 0 (0)
 Febrile neutro-
penia
0 0 2 0 2 (4.8)
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probelaparotomy, and CCRT and radiation were used for 
the 2 patients judged unable to receive post-NAC surgery, 
but all 3 of these patients developed intrapelvic recurrence.
The median follow-up period for 42 patients was 
45 months (range, 8–143), and the 5-year PFS rate and 
5-year OS rate were 67.2 % and 68.0 %, respectively. As 
to progression, the 5-year PFS rates for patients at stages I, 
II, and III were 53.3 %, 78.4 %, and 25.0 %, respectively, 
and the 5-year OS rates were 53.3 %, 79.2 %, and 25.0 %, 
respectively (Figs. 2, 3). In multivariate analysis of OS, 
lymph node metastasis before NAC [hazard radio (HR), 
34.88; p = 0.0031] and response of NAC (HR, 30.58; 
p = 0.0014) were extracted as significant prognosis factors 
(Table 6).
Discussion
Clinical studies of NAC for various forms of cancer are 
underway, but as yet there is little evidence of the useful-
ness of NAC in the field of gynecology including cervical, 
endometrial, and ovarian cancers. The clinical significance 
of NAC for cervical cancer is that the following can be 
expected: (1) tumor size reduction, which improves opera-
tive curability and safety and thus expands the surgical 
indications; and (2) inhibition of distant metastasis based 
on systemic effects being exerted on latent and lymph node 
micrometastatic lesions. As such, NAC for cervical cancer 
in Japan is currently performed to improve operative cur-
ability and safety as well as to increase the indications for 
surgery. However, there are no reports indicating that NAC 
prolongs survival.
A key drug for progressive recurrent cervical cancer is 
CDDP; the results of a randomized study by the Gyneco-
logic Oncology Group (GOG) demonstrated the useful-
ness of paclitaxel and topotecan in addition to CDDP, and 
dual therapy with CDDP has been recommended for recur-
rence and progressive cancer [12, 13]. Topotecan is widely 
used in Western countries, whereas mainly CPT-11, with a 
mechanism of action based on the same DNA type I topoi-
somerase inhibitory action, is used in Japan.
In a study of combination therapy with CDDP [CDDP 
60 mg/m2 (day 1) + CPT-11 60 mg/m2 (days 1, 8, 15)], the 
response rate in patients with recurrent/progressive cervical 
Fig. 1  Operation consort 
diagram. SCC squamous cell 
carcinoma, NAC neoadjuvant 
chemotherapy
Table 4  Operative details
RH radical hysterectomy, TAH total abdominal hysterectomy, IQR 
interquartile range
Characteristic n = 42
Type of surgery 40
 RH 38
 TAH 1
 Probe laparotomy 1
 Inoperable 2
Operation time (min)
 Median (IQR) 260 (210–334)
Blood loss (ml)




Time from surgery to discharge (Days)
 Median (IQR) 21 (16–26)
Pathological lymph node metastasis
 Positive 13
 Negative 29
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cancer was 59.9 %, and the response rate when this regi-
men was administered as NAC was 78 % [6, 9]. To reduce 
the time to surgical therapy, the primary treatment, we con-
ducted a phase II clinical study of NAC in combination 
with radical hysterectomy with a dosing schedule involving 
a 21-day cycle with a higher than usual CDDP dose inten-
sity. The response rate in 42 patients was 83.3 %, better 
than the therapeutic results of Sugiyama et al. Notably, a 
response rate of 86.8 % was obtained in 38 patients with 
stage IB2 to IIB disease. However, the response rates were 
50.0 % in 4 stage IIIB patients, 50 % in operated patients, 
and 25 % in patients who had completed radical hysterec-
tomy. Our results indicate that NAC plus radical hysterec-
tomy is not useful in stage III patients.
With regard to adverse events, the incidence of grade 
3 or more severe neutropenia was 54.8 %, although this 
adverse event could be managed with a G-CSF agent. In 
all cases with diarrhea characteristic of CPT-11, the sever-
ity was grade 2 or lower. A single dose of CPT-11 had to 
be reduced in this regimen because of administration in 
divided doses on days 1 and 8, thereby preventing grade 3 
or more severe diarrhea.
In 40 patients undergoing NAC plus radical hysterec-
tomy, median operative time was 260 min and median sur-
gical blood loss was 500 ml, similar to those findings in 
studies of radical hysterectomy for patients with stage IB2 
to IIB with a bulky mass reported by He et al. and Wang 
et al. [14, 15]. No serious postoperative complications, such 
as intestinal obstruction and thrombosis, occurred. Accord-
ingly, this study demonstrated the safety of NAC plus radi-
cal hysterectomy, with no major adverse effects for patients.
We compared the treatment outcomes in our 38 IB2–IIB 
cases with the results reported by Uegaki et al. [16]. The 
response rate for our cases was 86.6 %, comparable to the 
rate reported by Uegaki et al. (86.2 %). The 5-year PFS 
(73.3 % vs. 62.2 %) and 5-year OS (78.9 % vs. 74.9 %) 
were better in our cases than in the cases reported by Uegaki 
et al. Comparisons were also made with respect to adjuvant 
therapy and recurrence sites. According to the report by 
Uegaki et al., recurrence was noted in 21 (32.3 %) of the 
65 cases, and 15 of these 21 cases had received adjuvant 
therapy, but recurrence in the pelvic cavity was observed 
in only 4 cases (the other cases of recurrence had remote 
metastasis, including metastasis to the paraaortic lymph 
nodes). Of the 38 patients we managed, 10 patients (26.3 %) 
developed recurrence, including 8 patients who received 
adjuvant therapy (4 patients with intrapelvic recurrence and 
the other 4 patients with metastasis to lymph nodes, includ-
ing the paraaortic lymph nodes). Postoperative adjuvant 
therapy by means of CCRT or radiation was performed in 
27 (93.1 %) of the 29 cases reported by Uegaki et al. and 
14 (50.0 %) of the 28 cases managed by us. Postoperative 
Table 5  Details of recurrent 
patients after radical 
hysterectomy (n = 38)
PAN paraaortic lymph node
Adjuvant therapy Number Rate (%) Recurrent sites
Chemoradiotherapy (n = 2) 1 50.0 PAN (l)
Chemotherapy (n = 15) 2 13.3 PAN (l), pelvic cavity (l)
Radiation (n = 12) 5 41.7 PAN (2), subclavicular lymph node (l), pelvic cavity (3)
No therapy (n = 9) 2 22.2 Vaginal stump (2)
Fig. 2  Kaplan–Meier plot of progression-free survival (n = 42)
Fig. 3  Kaplan–Meier plot of overall survival (n = 42)
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CCRT or radiation allowed control of intrapelvic recur-
rence to some extent, whereas postoperative chemotherapy 
tended to reduce the risk of remote recurrence. These results 
suggest that the site of recurrence depends on the type of 
postoperative adjuvant therapy. Furthermore, as recurrence 
was also observed in cases that did not receive postoperative 
adjuvant therapy, it seems advisable to perform postopera-
tive adjuvant therapy in all cases of bulky tumors.
Six randomized clinical trials (1036 patients) includ-
ing Study JCOG102 in Japan were analyzed in Cochrane 
Reviews in 2010, and NAC in combination with surgical 
therapy reportedly improved the disease-free survival rate 
as compared with initial surgery (HR, 0.76; p = 0.01). 
NAC plus radical hysterectomy was thus suggested to 
improve patient prognosis [17]. According to a multivari-
ate analysis of OS, clinical stages, lymph node metastasis 
before NAC, and antitumor effects are significant prog-
nostic factors. Therefore, it was suggested that NAC plus 
radical hysterectomy, for patients other than those with 
lymph node metastasis before NAC, may further improve 
the therapeutic effects of NAC. That is, the prognosis of 
patients with stage IB2 to IIB cervical cancer with a bulky 
mass might be improved by hysterectomy alone in those 
who have lymph node metastasis before NAC, and by 
NAC plus radical hysterectomy in those without lymph 
node metastasis. The next step we should take would be 
implementation of a phase II clinical study on the use of 
NAC plus radical hysterectomy plus adjuvant therapy, 
with details of postoperative adjuvant therapy set forth in 
advance, in patients having a bulky tumor (clinical stage 
IB2–IIB). The results from such a study would provide 
important data for planning a phase III clinical study on a 
national scale of NAC plus radical hysterectomy plus adju-
vant therapy versus radical hysterectomy plus adjuvant 
therapy versus CCRT.
Conclusions
The results of this study suggest that NAC, that is, the 
CDDP/CPT-11 regimen, in combination with radical 
hysterectomy exerts high antitumor efficacy with manage-
able adverse reactions. Thus, NAC may facilitate safe radi-
cal hysterectomy. This treatment strategy is considered to 
be therapeutically useful, and an improved prognosis can 
also be expected. Therefore, we add our evidence of the 
usefulness of NAC plus radical hysterectomy in Japan to 
the world literature on cervical cancer treatment.
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